![Philip Nickson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip Nickson
Algemeen Adviseur bij
MONTE ROSA THERAPEUTICS, INC.
Vermogen: 766 700 $ op 31-08-2026
Profiel
Philip Nickson is currently Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc. since 2024.
Previously, Dr. Nickson was Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Education includes a doctorate from The University of Manchester and a graduate degree from Suffolk University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-04-2026 | 55.000 ( 0,06% ) | 766 700 $ | 31-08-2026 |
Actieve functies van Philip Nickson
| Bedrijven | Functie | Begin |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Algemeen Adviseur | 01-03-2021 |
Eerdere bekende functies van Philip Nickson
| Bedrijven | Functie | Einde |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2021 |
Opleiding van Philip Nickson
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
58
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Suffolk University
 Suffolk University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
